GeneDx Reports Q3 2026 Revenue Growth Driven by Exome and Genome Testing
GeneDx Holdings Corp. (WGS) reported third-quarter revenue of $123.1 million, a 5% year-over-year increase. The company saw significant strength in its core exome and genome segments, which grew 12% year-over-year to $110.4 million. Profitability improved as adjusted gross margins expanded to 72%, contributing to an adjusted net income of $8.6 million compared to a near break-even result in the previous quarter. Despite strong performance, management issued a cautious outlook for full-year volume growth, adjusting targets downward from at least 30% to at least 28%. The company is navigating headwinds related to new pre-analytical documentation requirements that have caused some friction in order processing. Additionally, GeneDx warned of a mid-single-digit revenue headwind in 2027 due to PAMA exposure affecting approximately 45% of its revenue.
Tickers: $WGS
Topics: Gross Margin Expansion Net Income Improvement Revenue Growth Test Volume Growth